Down 88%, Could Editas Medicine Be a Good Investment Now?
It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ: EDIT) have collapsed by about 88% over the past three years despite recent positive news regarding its experimental therapies and intellectual property.
Editas is driving its first CRISPR-based therapy toward commercialization. Following approval of a similar treatment from CRISPR Therapeutics and partner Vertex Pharmaceuticals in December, its chances of achieving commercialization appear better than ever.
Is Editas Medicine a good investment following the approval of the first CRISPR-based drug? Let's weigh its strengths against the challenges it faces to find out.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 55 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 450 € is below the current price of 460.8 € for Vertex Pharmaceuticals Inc., so the potential is actually -2.34%.
